Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "Lupin"

316 News Found

Lupin receives USFDA approval for Brivaracetam Tablets
Drug Approval | December 23, 2022

Lupin receives USFDA approval for Brivaracetam Tablets


Lupin Diagnostics expands footprint in Central India
News | December 22, 2022

Lupin Diagnostics expands footprint in Central India

The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price


Lupin launches generic version of Pennsaid in the US
News | December 12, 2022

Lupin launches generic version of Pennsaid in the US

Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)


Lupin appoints Spiro Gavaris as President of U.S. Generics Business
People | December 09, 2022

Lupin appoints Spiro Gavaris as President of U.S. Generics Business

Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business


Briefs: Natco Pharma & Lupin
News | December 06, 2022

Briefs: Natco Pharma & Lupin

Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.


Briefs: Lupin and GMM Pfaudler
News | November 30, 2022

Briefs: Lupin and GMM Pfaudler

The joint venture will help both the parties to further develop the high-margin service business


Lupin's subsidiary MedQuimica acquires rights to nine brands from Bausch Health
News | November 29, 2022

Lupin's subsidiary MedQuimica acquires rights to nine brands from Bausch Health

The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness


USFDA inspects Lupin's Mandideep Unit-1 facility
News | November 25, 2022

USFDA inspects Lupin's Mandideep Unit-1 facility

The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site


Lupin signs MoU with Govt. of Rajasthan to strengthen healthcare system
Healthcare | November 22, 2022

Lupin signs MoU with Govt. of Rajasthan to strengthen healthcare system

LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes


Lupin Q2 FY2023 revenue remains flat
News | November 10, 2022

Lupin Q2 FY2023 revenue remains flat

Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.